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Plk3 is a member of the polo-like kinase family of serine/
threonine kinases (1–3). It has significant functions in cell cycle
progression, DNA damage, hypoxic response, and apoptosis by
participating in multiple cell signaling pathways (4 –10). Previous studies have shown that Plk3 expression is reduced in multiple human tumors and cancer cell lines, particularly lung
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carcinomas (11–13). Notably, reduced Plk3 expression levels
rather than mutations are associated with lung cancers (14).
PLK3⫺/⫺ mice are prone to developing larger and more highly
vascularized tumors in multiple organs, including the lung (15),
highlighting a critical role of Plk3 in tumorigenesis and tumor
angiogenesis as a tumor suppressor. Previous work has shown
that although the Plk3 mRNA level oscillates in the cell cycle, its
protein level remains fairly stable (16, 17), suggesting a potential disconnection between the transcript and polypeptide of
Plk3. Although ectopically expressed Plk3 has been shown to be
rapidly degraded in the nucleus (18), it is unclear whether degradation of Plk3 also occurs in the cytoplasm.
Nickel compounds are well-established environmental and
occupational lung carcinogens (19). Considered weak mutagens, these compounds promote tumorigenesis mainly through
epigenetic and metabolic pathways (20). One major effect of
nickel, in the form of the divalent ion (Ni(II)), is to stabilize the
␣ subunit of the HIF2 transcription factor by inhibiting prolyl
hydroxylases (PHDs) (20). This hypoxia-mimicking effect of
Ni(II) contributes significantly to nickel carcinogenesis by promoting cellular transformation and tumor progression (20).
Recent studies have shown that Plk3 phosphorylates and
destabilizes HIF-1␣ in a Von Hippel-Lindau tumor suppressor (pVHL)-independent fashion (9). Accordingly, PLK3⫺/⫺
murine embryonic fibroblasts (MEFs) exhibit a much higher
level of HIF-1␣ in response to Ni(II) or hypoxia (10, 15). These
data suggest that regulation of the hypoxic (or hypoxic-like)
responses through the HIF transcription factor may be a key
mechanism that connects Plk3 and nickel carcinogenesis (21).
Seven in Absentia Homologue 2 (SIAH2) is an evolutionally
conserved RING finger ubiquitin E3 ligase that is activated
and/or induced by a variety of stress conditions, including
hypoxia (22, 23). Thus, among the list of substrates of SIAH2
are those involved in hypoxia-associated functions, such as
PHDs (22, 23). SIAH2 positively regulates the hypoxic response
by promoting degradation of PHDs thereby stabilizing HIF-1␣
(22, 23). SIAH2 itself is also subjected to regulation by a number
of protein kinases that are activated by various stress condi2

The abbreviations used are: HIF, hypoxia-inducible factor; PHD, prolyl
hydroxylase; PBD, polo-box domain; WB, Western blotting; ANOVA, analysis of variance; pVHL, Von Hippel-Lindau tumor suppressor ; UPS, ubiquitinproteasome system; MEF, murine embryonic fibroblast; IP, immunoprecipitation; CHX, cycloheximide; eGFP, enhanced GFP; KD, kinase domain;
LSD, least significant difference.
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Elevated cellular response to hypoxia, which contributes to
cell transformation and tumor progression, is a prominent feature of malignant cells in solid tumors. Polo-like kinase 3 (Plk3)
is a serine/threonine protein kinase known to inhibit the cellular
response to hypoxia and tumorigenesis. Nickel compounds are
well-established human carcinogens that induce tumorigenesis
partly through their hypoxia-mimicking effects. Despite previous research efforts, the role of Plk3 in the hypoxic response
induced by hypoxia or nickel is not completely understood.
Here, we show that NiCl2 (Ni(II)) or hypoxia reduces the protein
level and shortens the half-life of cytoplasmic Plk3 in a ubiquitin-proteasome-dependent manner. We identify SIAH2, a
RING finger E3 ubiquitin ligase associated with the cellular
hypoxic response, to be the ubiquitin E3 ligase that mediates the
degradation of Plk3. We show that SIAH2 binds to Plk3 and
mediates its ubiquitination primarily through its polo-box
domain. We report that USP28, a deubiquitinase known to be
inhibitable by Ni(II) or hypoxia, may also contribute to the suppression of the Plk3 protein by Ni(II). We also show that Plk3 in
turn suppresses the SIAH2 protein level in a kinase activity-dependent manner. Our study revealed an interesting mutual regulation between Plk3 and SIAH2 and uncovered a regulatory
network that functions to fine-tune the cellular hypoxic response. We propose that suppression of Plk3 expression contributes to carcinogenesis and tumor progression induced by
nickel compounds.

Mutual regulation between Plk3 and SIAH2

Results
Ni(II) or hypoxia suppresses Plk3 expression
Given the involvement of Plk3 in the hypoxic response (10),
we examined whether Plk3 expression is regulated by Ni(II) in
A549 lung carcinoma and BEAS-2B lung branchial epithelial
cells. Western blotting (WB) showed that the protein level of
Plk3 could be inhibited by Ni(II) in dose- and time-dependent
manners (Fig. 1, A–D). As expected, the protein levels of
HIF-1␣ and VEGF-A were both increased by Ni(II) (Fig. 1, C
and D). Long-term and low-dose Ni(II) treatments led to persistently lowered levels of Plk3 and elevated levels of HIF-1␣
(Fig. 1E). We also observed reduced levels of Plk3 mRNA upon
Ni(II) treatments, which were accompanied by a corresponding
increase in the mRNA levels of VEGF-A (Fig. 1, G–J). The
activities of AKT and ERK were significantly suppressed,
whereas that of p38 was dramatically increased by Ni(II) (Fig.
1F). Given that PLK3 is a serum-inducible gene (17, 25), the
suppression of Plk3 mRNA by Ni(II) was likely a result of
reduced activities of ERK and AKT. The elevated VEGF-A
mRNA levels were clearly a result of Ni(II)-induced HIF activation (Fig. 1, C and D).
Ni(II) or hypoxia suppresses the Plk3 protein level primarily
through proteasome-mediated protein degradation
Multiple reports have shown that the mRNA level of Plk3
does not closely correlate with its protein level (8, 17, 21, 25).
Plk3 is considered an immediate early response gene whose
mRNA level can be quickly induced by serum growth factors
after serum starvation, whereas its protein level is stable
throughout the cell cycle (8, 17, 21, 25). To confirm this, we
checked the effect of serum on Plk3 protein expression. As
shown in Fig. 2A, there was no consistent increase in the Plk3
protein level after serum treatment despite the activation of
ERKs, manifested as the increased levels of phosphorylated
ERKs. This confirms the disconnection between the mRNA and
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protein levels of Plk3. The data also suggest that suppression of
the Plk3 mRNA level by Ni(II) may not contribute significantly
to the lowered Plk3 protein level.
UPS is a common mechanism for post-translational regulation of protein levels or functions (26, 27). To determine
whether the Plk3 protein is suppressed by Ni(II) through UPS,
we examined the effect of MG132, a specific inhibitor of the 26S
proteasome (28). Our results showed that inhibition of the proteasome largely prevented the effect of Ni(II) or hypoxia on Plk3
in both A549 and BEAS-2B cells (Fig. 2, B–E), indicating that
the Plk3 protein was indeed suppressed by Ni(II) or hypoxia
through UPS. To determine whether Ni(II) affects the half-life
of the Plk3 protein, we used cycloheximide (CHX) to inhibit
protein synthesis, and tracked the Plk3 protein level with or
without co-treatments with Ni(II) in A549 cells. We observed a
significant drop in the half-life of the Plk3 protein from 14 to 8 h
upon Ni(II) treatment (Fig. 2, F and G).
Ectopically expressed Plk3 protein has been shown to locate
in both the cytoplasm and the nucleus of HEK293T cells, but
nuclear Plk3 is quickly degraded via UPS (18). To determine
whether Plk3 degradation also occurs in the cytoplasm, we
checked the effect of Ni(II) on the Plk3 protein at the subcellular level in A549 cells. As shown in Fig. 2H, the endogenous Plk3
protein was only detectable in the cytoplasm. The cytoplasmic
Plk3 protein behaved in the same way as did the total Plk3 in
response to Ni(II) and MG132 shown in Fig. 2B. These data
indicate that nuclear Plk3 may indeed be very unstable and
that Ni(II)-mediated suppression of Plk3 also occurs in the
cytoplasm.
Given the evidence that Plk3 is degraded via UPS, we checked
whether Plk3 is ubiquitinated and whether Ni(II) can affect its
ubiquitination. We first transfected the plasmid expressing
FLAG-tagged ubiquitin into A549 cells followed by immunoprecipitation (IP) with an anti-FLAG antibody. WB with an
anti-Plk3 antibody showed that ubiquitination of the endogenous Plk3 protein after ectopic expression of ubiquitin was
detectable and significantly elevated by Ni(II) and/or MG132
(Fig. 2, I and J). We next co-transfected both plasmids expressing FLAG-tagged ubiquitin and GFP-tagged Plk3 into
HEK293T cells followed by the same IP experiment. We found
that ectopically expressed Plk3 was also ubiquitinated and that
Ni(II) and/or MG132 increased Plk3 ubiquitination, as shown
in both IP and total protein samples (Fig. 2K). We repeated the
experiment in Fig. 2K with extended controls. As shown in Fig.
2L, significant ubiquitination of endogenous Plk3 was detectable and enhanced by MG132 and/or Ni(II) when ubiquitin
alone was transfected into HEK293T cells. This was also the
case with ectopically expressed Plk3 when GFP-tagged Plk3
alone or GFP-tagged Plk3 and FLAG-tagged ubiquitin were
introduced into HEK293T cells (Fig. 2M). As expected, MG132
and/or Ni(II) elevated ubiquitination of ectopically expressed
Plk3. In contrast, much lower levels of ubiquitinated endogenous Plk3 were detected in HEK293T cells after co-transfection
of empty GFP and FLAG vectors despite that MG132 enhanced
the levels of the endogenous Plk3 in both control and nickeltreated cells (Fig. 2N).
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tions, including hypoxia (22, 23). Accumulating evidence supports a prominent role of SIAH2 in multiple cancers (23, 24). Of
particular relevance, elevated expression of SIAH2 has been
detected in lung cancers (23, 24).
In this study, we investigated the regulation of Plk3 by Ni(II)
and hypoxia. We found that the Plk3 protein level can be suppressed by Ni(II) or hypoxia in lung carcinoma, lung epithelial,
and HEK293T cells. The suppression is mediated mainly by the
ubiquitin-proteasome system (UPS). SIAH2, a hypoxia-responsive E3 ubiquitin ligase, interacts with and mediates Plk3 degradation by UPS. The polo-box domain (PBD) of Plk3 appears
to be the primary motif that mediates the interaction between
Plk3 and SIAH2 as well as degradation of Plk3. We observed
that the SIAH2 protein level can be induced by Ni(II). The deubiquitinase USP28 may also be involved in Plk3 degradation in
response to Ni(II). Interestingly, Plk3 in turn suppresses the
protein level of SIAH2 in a manner dependent on the kinase
activity of Plk3. Together, our study revealed a potentially
important regulatory network involving Plk3, SIAH2, and
the HIF transcription factor. This network may function to
fine-tune the cellular hypoxic response and contribute to
carcinogenesis.

Mutual regulation between Plk3 and SIAH2
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Figure 1. Ni(II) suppresses Plk3 expression. A, A549 lung carcinoma cells were treated with NiCl2 at the indicated concentrations for 24 h and harvested for
total cellular proteins with 1⫻ sample buffer. Total cellular proteins were subjected to WB with the indicated antibodies. GAPDH was used as loading control.
B, experiment was performed as in A with BEAS-2B cells instead. C, A549 cells were treated with 0.5 mM NiCl2 for the indicated periods of time and then
processed as in A. D, experiment was performed as in C with BEAS-2B cells. E, A549 cells were cultured for 6 weeks (passed every 3 days) using media containing
0 or 100 M NiCl2. Cells were harvested at indicated time periods and then processed as in A. F, A549 cells were treated with 0.5 mM NiCl2 for the indicated
periods of time. Cells were then harvested for total proteins and subjected to WB with the indicated antibodies (P-AKT, phospho-AKT; P-p38, phospho-p38). G
and H, A549 cells were treated with NiCl2 at the indicated concentrations for 24 h and harvested for total RNA with TRIzol reagent as described under
“Experimental procedures.” Total RNA samples were then subjected to real-time PCR analysis for Plk3 and VEGF-A mRNA levels as described under “Experimental procedures.” GAPDH mRNA levels were used an internal control. I and J, A549 were treated with 0.5 mM NiCl2 for indicated periods of time and then
processed as in G and H. Data in A–F are representative of three or more independent experiments. Data in G–J are presented as mean ⫾ S.D. (n ⫽ 3, *, p ⬍ 0.05;
**, p ⬍ 0.01; ***, p ⬍ 0.001).

USP28 contributes to the suppression of Plk3 by Ni(II)
A previous study showed that the protein level of USP28, a
deubiquitinase known to regulate MYC and HIF-1␣ (29 –31),
can be inhibited by Ni(II) or hypoxia in an HIF-dependent fashion (32). To check whether USP28 is also involved in the suppression of Plk3 by Ni(II) or hypoxia, we co-transfected FLAG-

tagged ubiquitin and HA-tagged USP28 into A549 cells and
examined the response of the endogenous Plk3 protein level. As
shown in Fig. 3A, whereas USP28 did not significantly affect the
basal level of Plk3 protein, it was able to largely reverse the
suppressive effect of Ni(II) on Plk3. However, ectopic expression of USP28 without ubiquitin failed to prevent the suppresJ. Biol. Chem. (2017) 292(27) 11431–11444
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sion of endogenous Plk3 (Fig. 3, B and C), indicating that the
effect of USP28 on the Plk3 protein requires the presence of
excessive ubiquitin. Similar results were observed on the ectopically expressed Plk3 protein in HEK293T cells where GFPtagged Plk3 was transfected with or without FLAG-tagged
ubiquitin (Fig. 3, D–F). These data demonstrate that USP28 is
able to stabilize Plk3 in the presence of ectopically expressed
ubiquitin, likely by reducing its ubiquitination and preventing
subsequent degradation. Note that the protein level of ectopically expressed USP28 could be inhibited by Ni(II) (Fig. 3, A–F),
confirming the previous observation (32). The suppression of
the ectopically expressed USP28 driven by a CMV promotor
in the expression plasmid by Ni(II) suggests that this process is

11434 J. Biol. Chem. (2017) 292(27) 11431–11444

unlikely dependent completely on HIF-mediated transcriptional events. This observation is in agreement with the previous report (32).
To determine whether Plk3 can interact with USP28 directly,
we ectopically expressed HA-tagged USP28 in A549 cells and
performed a reciprocal IP with an anti-Plk3 antibody and an
anti-HA antibody. As shown in Fig. 3, G and H, we did not
detect any interaction between Plk3 and USP28. Similar IP
experiments using HEK293T cells ectopically co-expressing
Plk3 and USP28 produced the same result (Fig. 3, I and J). In
contrast, specific interactions between Plk3 and HIF-1␣ as well
as between USP28 and c-Myc were detectable (Fig. 3, G and H),
as demonstrated in previous studies (10, 30). These data indi-
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Figure 2. The Plk3 protein level is suppressed by Ni(II) or hypoxia primarily through proteasome-mediated protein degradation pathway. A, A549 cells
were serum-starved overnight followed by treatment with 10% FBS for the indicated periods of time. Total cellular proteins were collected and subjected to WB
with the indicated antibodies (P-ERK, phospho-ERK). B, A549 cells were either left untreated (C) or treated with 0.5 mM NiCl2 (Ni) with or without the presence
of 1 M MG132 for 24 h. Cells were then harvested for WB with the indicated antibodies. Relative levels of Plk3 expression were determined by densitometry
as shown at the bottom. C, A549 cells were treated with normoxia (N) or 1% O2 (H) for 24 h and then processed as in A. D, A549 cells were treated with normoxia
(N) or 1% O2 (H) with or without the presence of 5 M MG132 for 24 h. Cells were then harvested for WB with the indicated antibodies. Relative levels of Plk3
expression were determined by densitometry as shown at the bottom. E, experiment was performed as in D in BEAS-2B cells. F, A549 cells were treated with 50
g/ml cycloheximide with or without the presence of 0.5 mM NiCl2 for the indicated periods of time. Cells were then harvested for WB with the indicated
antibodies. G, Plk3 protein signals shown in F were quantified by densitometry scanning, and the data were plotted. H, A549 cells were either left untreated (C)
or treated with 0.5 mM NiCl2 (Ni) with or without the presence of 1 M MG132 for 24 h. Cell fractionation assay was then performed as described under
“Experimental procedures.” Proteins from cytosol and nucleus were subjected to WB with indicated antibodies. I and J, A549 cells were transfected with either
an empty vector (V) or a plasmid expressing FLAG-tagged ubiquitin (FLAG-Ub) for 24 h. Cells were then either left untreated (C) or treated with 0.5 mM NiCl2 (Ni)
with or without the presence of 10 M MG132 for 6 h. Total cellular proteins were collected and subjected to immunoprecipitation (IP) with an anti-FLAG
antibody. The total cellular proteins (inputs, I) and IP products (J) and were then subjected to WB with the indicated antibodies. K, HEK293T cells were
co-transfected with expression plasmids encoding FLAG-Ub and GFP-Plk3 for 24 h and then either left untreated (C) or treated with 0.5 mM NiCl2 (Ni) for 24 h
with or without the presence of 10 M MG132 for 4 h. Cells were then processed with IP and WB as in I and J. DM, DMSO; MG, MG132. L–N, HEK293T cells were
transfected with the expression plasmid encoding FLAG-Ub (L), or GFP-Plk3 (M), or FLAG-Ub and GFP-Plk3 (M), or FLAG vector (FLAG-V) and GFP vector (GFP-V)
(N). Cells were then treated as in K and analyzed with WB using the indicated antibodies. Data shown are representatives of three or more independent
experiments.

Mutual regulation between Plk3 and SIAH2

cate that the effect of USP28 on the suppression of the Plk3
protein level by Ni(II) probably works through an indirect
mechanism. It is also possible that the interaction between Plk3
and USP28 is weak and/or transient, which requires a more
sensitive assay to detect.
Given that both Ni(II) and hypoxia reduce the Plk3 protein
level and that these two conditions are both known to activate
the HIF transcription factor by stabilizing its ␣ subunit, we
checked whether the suppression of Plk3 by Ni(II) is HIF-dependent. Our data show that the HIF pathway is unlikely to
be directly involved in this process as ectopic expression or
siRNA-mediated knockdown of HIF-1␣ showed limited effects
on the Plk3 protein level (supplemental Fig. S1, A and B). Moreover, ectopic expression of pVHL or PHDs had little effect on
the level of the Plk3 protein (supplemental Fig. S1, C–E). Furthermore, the CRL family ubiquitin ligases, which regulate
HIF-␣ degradation, are unlikely involved in this process either

because inhibition of this family of E3 ligases did not affect the
Plk3 protein level (supplemental Fig. S1, F and G).
SIAH2 interacts with Plk3, mediates its ubiquitination, and
promotes its degradation in response to Ni(II) or hypoxia
In search for the E3 ubiquitin ligase that mediates Plk3 ubiquitination in response to Ni(II) or hypoxia, SIAH2 caught our
attention. SIAH2 is a RING finger E3 ubiquitin ligase that stabilizes HIF-1␣ by promoting ubiquitination and degradation of
PHDs in response to hypoxia (22). Given that both Ni(II) and
hypoxia inhibit Plk3 protein expression, we reasoned that
SIAH2 could be the E3 ligase that mediates Plk3 ubiquitination
and degradation. To test this, we first checked whether menadione, an SIAH2 inhibitor (33), could reverse the inhibitory
effect of Ni(II) on the Plk3 protein level. As shown in Fig. 4, A
and B, menadione dose-dependently elevated the basal level of
Plk3 protein and reversed the suppressive effect of Ni(II). SimJ. Biol. Chem. (2017) 292(27) 11431–11444
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Figure 3. Inhibition of Plk3 protein expression by Ni(II) can be reversed by deubiquitinase USP28. A, A549 cells were transfected with expression
plasmids encoding FLAG-Ub along with either empty vector (HA-vector) or HA-tagged USP28 (HA-USP) for 24 h. Cells were then either left untreated (C) or
treated with 0.5 mM NiCl2 (Ni) for 24 h. Total cellular proteins were then harvested for WB with an anti-Plk3 antibody to detect Plk3, an anti-HA antibody to detect
HA-USP28, and an anti-FLAG antibody to detect FLAG-Ub. B and C, experiments were performed as in A either with replacement of the FLAG-Ub vector with the
empty FLAG vector (FLAG-V) or without any FLAG vector. D, HEK293T cells were co-transfected with expression plasmids encoding FLAG-Ub, GFP-Plk3, and
either an empty vector (HA-vector) or HA-tagged USP28 (HA-USP) for 24 h. Cells were either left untreated (C) or treated with 0.5 mM NiCl2 (Ni) for an additional
24 h. Cells were then harvested for WB with the indicated antibodies. E and F, experiments were performed as in D either with replacement of the FLAG-Ub
vector with FLAG-V or without any FLAG vector. G, A549 cells were transfected with expression plasmids encoding either empty HA-vector (V) or HA-USP28
(USP) for 24 h. Cellular proteins were subjected to IP with an anti-Plk3 antibody followed by WB with an anti-HA antibody to detect HA-USP28 and other
indicated antibodies. H, experiment was performed as in G but with IP using an anti-HA antibody followed by WB using an anti-Plk3 antibody and other
antibodies as indicated. I, HEK293T cells were co-transfected with expression plasmids encoding GFP-Plk3 and either an empty HA-vector (V) or HA-USP28 (USP)
for 24 h. Cells were then processed as in G. J, experiment was performed as in I but with IP using an anti-HA antibody. WB was performed as in H. Data shown
are representatives of three or more independent experiments.

Mutual regulation between Plk3 and SIAH2

ilar reversal effects were also observed under hypoxia (Fig. 4C).
We next determined whether SIAH2 can reduce the protein
level of Plk3. We ectopically expressed SIAH2 and Plk3 into
HEK293T cells and then measured Plk3 protein levels with or
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without the presence of menadione. As shown in Fig. 4D,
ectopic expression of SIAH2 strongly reduced the Plk3 protein
level, and menadione largely prevented this effect. Note that the
level of SIAH2 was also raised by menadione, consistent with
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Figure 4. SIAH2 interacts with Plk3 and suppresses its protein expression. A, A549 cells were treated with either DMSO (vehicle, DM) or menadione at the
indicated concentrations with or without the presence of 0.5 mM NiCl2 for 24 h. Total cellular proteins were then collected and subjected to WB with the
indicated antibodies. Relative levels of Plk3 expression (upper row) and ratios of nickel-treated and -untreated (lower row) were determined by densitometry as
shown at the bottom. B, experiment was performed as in A with a higher concentration of menadione (M). C, A549 cells were treated with either DMSO or 5 M
MG132 or different concentrations of menadione (MND) under either normoxia (N) or 1% O2 (H) for 24 h. Cells were harvested for total cellular proteins and
subjected to WB with the indicated antibodies. Relative levels of Plk3 expression (upper row) and ratios of hypoxia-treated and -untreated (lower row) were
determined by densitometry as shown at the bottom. D, HEK293T cells were co-transfected with expression plasmids encoding GFP-Plk3 along with either an
empty vector (V) or HA-SIAH2-WT. Forty two hours after transfection, cells were treated with either DMSO (vehicle, DM) or menadione (MND) at the indicated
concentrations for 6 h. Cells were then subjected to WB with the indicated antibodies. E, HEK293T cells were co-transfected with expression plasmids encoding
either HA-PHD3 or GFP-Plk3 together with either an empty vector (V), HA-SIAH2-WT (WT), and HA-SIAH2-RING mutant (M) for 48 h. Cells were then harvested
for total proteins and subjected to WB with the indicated antibodies. F, stable knockdown of SIAH2 in HEK293T cells were carried out as described under
“Experimental procedures.” Cells were then seeded into 6-cm culture dishes. Twenty four hours later, cells were treated with 50 g/ml cycloheximide,
harvested at the indicated periods of time after the treatment, and subjected to WB with the indicated antibodies. V, control shRNA; SIAH2, SIAH2 shRNA. G,
HEK293T cells with or without stable knockdown of SIAH2 described in F were treated with normoxia (N) or 1% O2 (H) for 6 h and then harvested for WB with
the indicated antibodies. H, HEK293T cells were transfected with either a scrambled (C) or a SMARTpool siRNA oligonucleotide targeting SIAH2 at the indicated
concentrations. Cells were harvested 96 h post-transfection and analyzed by WB with the indicated antibodies. I, HEK293T cells were co-transfected with
expression plasmids encoding GFP-Plk3 along with either an empty vector (V), HA-SIAH2-WT (WT), or HA-SIAH2-RM (M). Forty two hours after transfection, cells
were treated with 10 M MG132 for an additional 6 h. Cells were then lysed and subjected to IP using an anti-SIAH2 antibody. Total proteins and IP products
were subjected to WB with the indicated antibodies. J, HEK293T cells were transfected with expression plasmids encoding either an empty vector (V) or
HA-SIAH2-WT (SIAH2) for 42 h followed by treatment with 10 M MG132 for an additional 6 h. Cells were then lysed and subjected to IP with an anti-SIAH2
antibody or normal IgG (as control). Total proteins and IP products were subjected to WB with the indicated antibodies. K, A549 cells were treated with 10 M
MG132 for 6 h before harvesting for IP with an anti-SIAH2 antibody or normal IgG followed by WB with the indicated antibodies. L, HEK293T cells were
co-transfected with expression plasmids encoding GFP-Plk3, FLAG-Ub, and the empty vector (V) or HA-SIAH2-WT (HA-SIAH2) for 36 h followed by treatment
with 10 M MG132 for an additional 12 h. Cells were then lysed and subjected to IP using an anti-GFP antibody followed by WB with the indicated antibodies.
Ubiquitinated Plk3 was detected with an anti-FLAG antibody. M, HEK293T cells were co-transfected with expression plasmids encoding GFP-Plk3,
HA-SIAH2-WT (HA-SIAH2), and the empty FLAG vector (FLAG-V) or FLAG-Ub for 42 h followed by treatment with 20 M MG132 for an additional 6 h. Cells were
then lysed and subjected to IP using an anti-Plk3 antibody. The inputs and IP products were then subjected to WB with the indicated antibodies. Data shown
are representatives of three or more independent experiments.

Mutual regulation between Plk3 and SIAH2
We next asked whether SIAH2 can directly interact with
Plk3. We co-transfected GFP-tagged Plk3 with either wild-type
or mutant SIAH2 into HEK293T cells followed by IP with an
anti-SIAH2 antibody. As shown in Fig. 4I, a significant amount
of Plk3 appeared in the immunocomplex of both the wild-type
and mutant SIAH2 despite the weak nonspecific signal in the
vector group. We next transfected only SIAH2 followed by
immunoprecipitation with the anti-SIAH2 antibody. We found
that the SIAH2 antibody but not normal IgG could immunoprecipitate endogenous Plk3 (Fig. 4J). Finally, immunoprecipitation of endogenous SIAH2 in A549 cells using an anti-SIAH2
antibody showed that the anti-SIAH2 antibody but not normal
IgG could precipitate endogenous Plk3 (Fig. 4K). Together, our
data establish that Plk3 physically and physiologically interacts
with SIAH2.
Given that SIAH2 is a ubiquitin E3 ligase, we next checked
whether SIAH2 promotes Plk3 ubiquitination. We co-expressed GFP-tagged Plk3 with either FLAG-tagged ubiquitin or
FLAG-tagged ubiquitin along with HA-tagged SIAH2 in
HEK293T cells. We then immunoprecipitated ectopically
expressed Plk3 with an anti-GFP antibody and detected the
level of ubiquitinated Plk3 using WB with an anti-FLAG antibody. As shown in Fig. 4L, co-expression of SIAH2 markedly
elevated the level of ubiquitinated Plk3. Similar IP experiments
using an anti-Plk3 antibody yielded an identical result (Fig.
4M). The lowered GFP-Plk3 levels in groups co-expressing
SIAH2 further confirm the inhibition of Plk3 protein expression by SIAH2 (Fig. 4, L and M). These data together with the
observation that SIAH2 directly interacts with Plk3 clearly
show that SIAH2 directly mediates Plk3 ubiquitination.
SIAH2 binds to Plk3 and mediates Plk3 degradation primarily
through its polo-box domain
Plk3 consists of an N-terminal kinase domain (KD) that confers its catalytic activity and a C-terminal PBD that mediates
substrate recognition as well as protein-protein interaction
(21). Given the observed regulation of Plk3 by SIAH2, we asked
which domain of Plk3 is important for its interaction with
SIAH2 and degradation. We co-transfected HA-tagged wildtype SIAH2 along with either the empty FLAG vector or various
FLAG-tagged Plk3 constructs (full-length, KD, and PBD) into
HEK293T cells. SIAH2 is known to promote its own degradation by self-ubiquitination (23). To reduce this effect, we added
MG132 6 h before harvesting cells. We then performed IP with
an anti-SIAH2 antibody and checked for potential co-IP of the
Plk3 protein using WB with an anti-FLAG antibody. We found
that both full-length and deletion mutants of Plk3 were able to
interact with SIAH2 (Fig. 5A, right panel).
When comparing the results from the input and the IP, we
noticed that although the KD of Plk3 was expressed at the highest level (Fig. 5A, left panel, 3rd lane), it co-IP with SIAH2 at the
lowest level (Fig. 5A, right panel, 3rd lane). In contrast, although
PBD was expressed at the lowest level (Fig. 5A, left panel, 4th
lane), it co-IP with SIAH2 at a much higher level, almost equivalent to that of full-length Plk3 (Fig. 5A, compare 2nd lane with
4th lane of the right panel). These data indicate that SIAH2 had
the strongest interaction with PBD. We next performed the
same co-IP experiment with the ligase-deficient mutant SIAH2
J. Biol. Chem. (2017) 292(27) 11431–11444
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the notion that SIAH2 can mediate its own ubiquitination and
degradation (23).
SIAH2 is known to promote ubiquitination and degradation
of PHD3 thereby stabilizing HIF-1␣ (22, 23). Using this regulation as a positive control, we examined whether ectopically
expressed SIAH2 can suppress ectopically expressed Plk3. We
co-expressed wild-type or E3 ligase-deficient SIAH2, which
contains a point mutation within its RING domain (34), along
with either the HA-tagged PHD3 or GFP-tagged Plk3 in
HEK293T cells followed by WB. As shown in Fig. 4E, we
observed similar effects of SIAH2 on PHD3 and Plk3: wild-type
but not E3 ligase-deficient SIAH2 reduced PHD3 and Plk3 levels. Note that wild-type SIAH2 was expressed at a much lower
level than the E3 ligase-deficient one, consistent with its selfubiquitination property (23). Importantly, reduced PHD3 or
Plk3 expression as a result of co-expression of wild-type SIAH2
correlated with increased levels of VEGF-A (Fig. 4E). These
data suggest that, as with PHD3, inhibition of the Plk3 protein
by SIAH2 may produce a biological effect by altering VEGF-A
expression.
To determine the effect of endogenous SIAH2 on endogenous Plk3 protein expression, we stably depleted SIAH2 using
shRNA in HEK293T cells and chased the protein level of Plk3
over time after treating the cells with CHX to inhibit the protein
synthesis. As shown in Fig. 4F, the basal (time 0) SIAH2 protein
level was much lower in SIAH2 knockdown cells than in the
control cells, indicating significant knockdown of SIAH2. In
contrast, the basal Plk3 protein level was significantly higher in
SIAH2 knockdown cells. The decay of the Plk3 protein level was
also slower in SIAH2 knockdown cells than in the control cells
after CHX treatment (Fig. 4F). These data confirm that degradation of Plk3 is indeed negatively correlated with the level of
SIAH2 at physiological conditions.
To explore the potential functional significance of the regulation of Plk3 by SIAH2, we treated the SIAH2 knockdown
HEK293T cells and the control cells with hypoxia and examined the effect of SIAH2 knockdown on the protein levels of
VEGF-A and HIF-1␣, two known downstream targets of SIAH2
and Plk3 (10, 15, 22, 23). Our results showed that both the basal
and hypoxia-induced HIF-1␣ and VEGF-A levels were lower in
SIAH2 knockdown cells than in control cells. In contrast, the
levels of the Plk3 protein in both normoxic and hypoxic conditions were higher in SIAH2 knockdown cells than in control
cells (Fig. 4G). Note that the SIAH2 protein levels were much
lower in SIAH2 knockdown cells and elevated under hypoxia,
consistent with previous findings (22, 23). These results indicate that SIAH2 may work with Plk3 to regulate the hypoxic
response, through which production of angiogenic factors is
altered.
To further confirm the regulation of Plk3 by SIAH2 at the
endogenous level, we used siRNA to transiently knock down
SIAH2, and measured the effect on the Plk3 protein level. As
shown in Fig. 4H, dose-dependent depletion of endogenous
SIAH2 using siRNA led to dose-dependent increases in the
endogenous Plk3 protein in HEK293T cells. Together, our
data strongly support the notion that SIAH2 helps suppress
the level of Plk3 protein by facilitating Plk3 ubiquitination
and degradation.
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and found that PBD was expressed at a much higher level (Fig.
5, A and B, compare 4th lane of the left panels), suggesting that
the stability of PBD is highly sensitive to the E3 ligase activity of
SIAH2. Again, all three Plk3 proteins interacted with mutant
SIAH2, confirming the result in Fig. 5A. This result also suggests that the E3 ligase activity is not required for the interaction between Plk3 and SIAH2. Similar to the wild-type SIAH2,
although the KD of Plk3 had the highest level of expression, it
interacted with SIAH2 the least (Fig. 5B, right panel, 3rd lane).
These data establish that although both the KD and PBD of Plk3
can interact with SIAH2, binding between PBD and SIAH2 is
much stronger. Consistently, PBD was more susceptible to
SIAH2-mediated degradation (Fig. 5, A and B).
To further confirm the SIAH2-mediated degradation of Plk3,
we repeated the transfection experiments described in Fig. 5, A
and B, with or without treatment with the proteasome inhibitor
MG132. Our results showed that wild-type SIAH2 suppresses
the Plk3 protein level in a proteasome-dependent fashion, manifested as higher levels of the Plk3 protein in the mutant SIAH2
groups than in the wild-type SIAH2 groups and in MG132treated groups than in the untreated groups (Fig. 5C, compare
FLAG signals between groups). These data also confirm that
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PBD is responsible for much of the SIAH2-mediated degradation of the Plk3 protein as the levels of PBD were much higher in
the mutant SIAH2 groups than in the wild-type SIAH2 groups
(Fig. 5C, compare FLAG signals between wild-type and mutant
SIAH2 groups). Furthermore, inhibition of the proteasome significantly increased the level of PBD, especially in the wild-type
SIAH2 group (Fig. 5C, compare FLAG signals between MG132treated and -untreated groups). In contrast, the levels of KD
remained relatively constant regardless of the treatments and
SIAH2 mutation status (Fig. 5C). Note that the HIF-1␣ protein
levels were elevated as a result of ectopic expression of wildtype SIAH2 but not mutant SIAH2 and that inhibition of the
proteasome increased the endogenous HIF-1␣ protein levels in
both wild-type and mutant SIAH2 groups (Fig. 5C). These
results are consistent with the previous findings that SIAH2
up-regulates the HIF-1␣ protein level by promoting ubiquitination and degradation of the prolyl hydroxylase (22). Also note
that wild-type SIAH2 was expressed at very low levels, which
required long exposure to detect and were significantly elevated
by inhibition of the proteasome (Fig. 5C, HA versus HA-L). In
contrast, mutant SIAH2 was expressed at much higher levels
and MG132 only had a very small effect on its expression. These
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Figure 5. SIAH2 binds to both the KD and PBD domains of Plk3 but targets Plk3 degradation mainly through the PBD domain. A, HEK293T cells were
co-transfected with expression plasmids encoding HA-tagged wild-type SIAH2 (HA-SIAH2-WT) along with either FLAG vector (FLAG-Vector), FLAG-tagged Plk3
full-length (FLAG-Plk3-FL), FLAG-tagged Plk3 kinase domain (FLAG-Plk3-KD), or FLAG-tagged Plk3-Polo-box domain (FLAG-Plk3-PB) for 42 h followed by treatment with 10 M MG132 for an additional 6 h. Cells were then lysed and subjected to IP using an anti-SIAH2 antibody followed by WB with the indicated
antibodies. B, HEK293T cells were co-transfected with expression plasmids encoding HA-tagged SIAH2-RING mutant (HA-SIAH2-m) along with either FLAGVector, FLAG-Plk3-FL, FLAG-Plk3-KD, or FLAG-Plk3-PB for 48 h. Cells were then harvested for WB with the indicated antibodies. C, HEK293T cells were cotransfected with expression plasmids encoding HA-SIAH2-WT or HA-SIAH2-m along with either FLAG-Vector, FLAG-Plk3-FL, FLAG-Plk3-KD, or FLAG-Plk3-PB.
Forty two hours after transfection, cells were treated with either DMSO (vehicle) or 10 M MG132 for an additional 6 h. Cells were then harvested for total cellular
proteins and subjected to WB with the indicated antibodies. D, schematic diagram of Plk3 with the two possible SIAH2 interaction regions indicated. E,
HEK293T cells were co-transfected with expression plasmids encoding HA-SIAH2-m with either GFP-tagged vector (GFP-Vector), Plk3-full-length (GFP-Plk3-FL),
Plk3-Kinase domain (GFP-Plk3-KD), Plk3-Polo-box domain (GFP-Plk3-PB), or Plk3-Kinase domain mutant-KDT219D (GFP-Plk3-KDM). Cells were lysed and processed as in C 48 h after transfection. F, littermate-paired WT and PLK3⫺/⫺ MEFs were cultured as described under “Experimental procedures” and harvested for
WB with indicated antibodies. Plk3 was detected with the Fnk antibody. Data shown are representatives of three or more independent experiments.
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Plk3 regulates SIAH2 stability in a kinase activity-dependent
fashion
During the analysis of our co-transfection experiments
investigating the regulation of Plk3 by SIAH2, we observed that
ectopic co-expression of full-length Plk3 or the KD but not the
PBD of Plk3 dramatically inhibited the protein levels of both
wild-type and mutant SIAH2 (Fig. 5, A–C, HA signals). Note
that the KD of Plk3 showed a stronger effect than full-length
Plk3. These data suggest that Plk3 regulates SIAH2 stability in a
KD-dependent manner. To confirm this, we repeated the cotransfection experiment shown in Fig. 5B using GFP-tagged
Plk3 expression plasmids (as oppose to FLAG-tagged constructs in Fig. 5B), with an additional group co-transfected with
a plasmid encoding the Plk3 KD containing a T219D point
mutation that renders it kinase activity deficient (15). Our
results showed that GFP-tagged Plk3 had the same effect on
mutant SIAH2 as did FLAG-tagged Plk3 (compare HA signals
of the 1st 4 lanes of Fig. 5E with HA signals of B). As expected,
mutant Plk3 KD had a much reduced ability of suppressing the
level of mutant SIAH2 (Fig. 5E, HA signals, compare 3rd lane
with 5th lane). These results confirm that SIAH2 was indeed
suppressed by Plk3 in a kinase activity-dependent manner.
Finally, we checked whether the SIAH2 protein level is altered
under the conditions where Plk3 is absent using MEFs isolated
from littermates of wild-type and PLK3 knock-out mice (10). As
indicated in Fig. 5F, the SIAH2 protein level is significantly
higher in PLK3⫺/⫺ MEFs, supporting the notion that Plk3 suppresses SIAH2 protein expression.
The SIAH2 protein level is regulated by Ni(II)
Given that Ni(II) suppresses the Plk3 protein level and that
SIAH2 mediates Plk3 ubiquitination and degradation, we asked
whether SIAH2 is regulated by Ni(II). The level of SIAH2 protein has been shown to increase under various stress conditions, including hypoxia (23). The level or activity of SIAH2 is
also subjected to regulation by a number of protein kinases,
including the p38 MAPK (23). To explore whether and how
Ni(II) may regulate SIAH2, we first treated HEK293T cells with
Ni(II) for 6 h with or without the presence of MG132 and exam-

ined the effect on the endogenous SIAH2 protein level. We
found that Ni(II) treatments resulted in a significant increase in
the SIAH2 protein level regardless of the presence of MG132
(Fig. 6A). We then performed a side-by-side comparison of the
responses in HEK293T and A549 cells using the same experimental protocol. As shown in Fig. 6B, Ni(II) elevated endogenous SIAH2 protein levels in both HEK293T and A549 cells.
We next examined the effect of Ni(II) on ectopically expressed
SIAH2. We transfected either the empty vector or the HAtagged wild-type SIAH2 into HEK293T cells followed by Ni(II)
treatment for 6 h before harvesting for WB analysis. As shown
in Fig. 6C, Ni(II) significantly raised the level of ectopically
expressed SIAH2 (compare both SIAH2 and HA signals). The
results from these experiments establish that the SIAH2 protein level can indeed be induced by Ni(II).
Given our data showing that the Plk3 protein is mostly
located in the cytoplasm where nickel-induced degradation
occurs (Fig. 2H), we examined how the endogenous SIAH2 protein is regulated by Ni(II) in different subcellular locations. We
performed cell fractionation analyses on A549 cells with or
without the Ni(II) treatment. As shown in Fig. 6D, SIAH2
appeared in both the cytoplasm and the nucleus. Ni(II) treatments significantly raised the level of SIAH2 in the cytoplasm
but not in the nucleus. A similar pattern of cytoplasmic SIAH2
levels was detected when cells were treated with hypoxia (Fig.
6E). Note that the nuclear level of Plk3 was very low (Fig. 6D),
confirming the results shown in Fig. 2H. However, the nuclear
SIAH2 protein appeared to behave differently in response to
Ni(II) versus hypoxia, as indicated by the reduced level in presence of Ni(II) versus the slightly elevated level under hypoxia
(compare nuclear SIAH2 between Fig. 6, D and E). Nonetheless,
the increase in the level of cytoplasmic SIAH2 in response to
Ni(II) or hypoxia is in line with the notion that SIAH2 mediates
Plk3 ubiquitination and degradation in the cytoplasm where
Plk3 is predominantly located.
SIAH2 has been shown to be phosphorylated by p38 MAPK
under hypoxia thereby promoting its nuclear localization (23).
It has also been reported that activation of AKT by hypoxia
contributes to the increase in the SIAH2 protein level by promoting its transcription (23). Our data appear to agree with
these findings for the hypoxic condition (see Fig. 6E). However,
our results showed that the activities of AKT and ERK were
significantly suppressed by Ni(II) treatments, whereas that of
p38 was dramatically increased (Fig. 1F). These data exclude the
possibility that the elevated SIAH2 protein level in response to
Ni(II) is a direct result of AKT- or ERK-mediated transcriptional events. The dramatic increase in p38 activity in response
to Ni(II) prompted us to examine whether p38 activation affects
the suppression of the Plk3 protein level by Ni(II). As shown in
Fig. 6F, SB203580, a specific p38 inhibitor, at two different concentrations had no effect on the inhibition of the Plk3 protein
level by Ni(II). These results indicate that while showing some
similarities, the mechanisms underlying the regulation of Plk3
by SIAH2 in response to Ni(II) and hypoxia are not identical.

Discussion
The tumor-suppressive function of Plk3 and the evidence
connecting Plk3 to the hypoxic response and tumor angiogenJ. Biol. Chem. (2017) 292(27) 11431–11444

11439

Downloaded from http://www.jbc.org/ at New York Medical College on April 20, 2018

observations are consistent with the fact that mutant SIAH2
has limited E3 ligase activity toward itself (34).
SIAH2 binds to its substrates via a predicted consensus
sequence (PXAXVXP) (35, 36). We analyzed the amino acid
sequence of Plk3 and identified two regions that resemble the
consensus SIAH2-binding sequence (Fig. 5D). One site is
located within the kinase domain of Plk3 (239PEADVWS245).
The other site resides slightly N-terminal of the polo-box
domain (454PLAQPEP460). The first site contains a substitution
of proline (an aliphatic amino acid) by serine (a hydrophilic
residue) at the last position. The second site appears to be more
close to the consensus sequence, with a substitution of valine by
a proline (both are aliphatic) at the 5th position. The locations
and the characteristics of the two potential SIAH2-binding sites
are in line with our observations that although both the KD and
PBD of Plk3 bind to SIAH2, PBD has a much stronger interaction with SIAH2 and is more prone to degradation (Fig. 5, A
and B).

Mutual regulation between Plk3 and SIAH2

esis demonstrate a potential involvement of this protein kinase
in Ni(II) carcinogenesis as well as tumor progression in general.
In an effort to understand this process, we investigated the regulation of Plk3 protein expression by Ni(II) and hypoxia in this
study, with a focus on lung carcinoma and lung epithelial cells.
We found that Plk3 can be suppressed by Ni(II) or hypoxia in
these cells. We discovered a novel mechanism in which Ni(II)
induces expression of SIAH2, a RING finger ubiquitin E3 ligase,
which in turn directly mediates ubiquitination and subsequent
degradation of Plk3 by the proteasome. We also found that
USP28, a deubiquitinase known to be inhibited by Ni(II), may
also contribute to the inhibition of the Plk3 protein level by
Ni(II). We show that the PBD of Plk3 is the primarily domain
that mediates its interaction with SIAH2 and degradation by
UPS. We further revealed that Plk3 destabilizes SIAH2 in a
kinase activity-dependent manner. These novel findings provide new mechanistic insights on the role of Plk3 in Ni(II) carcinogenesis and tumor progression, particularly in the lung.
PLK3 is considered an immediate early response gene whose
mRNA expression is induced by serum growth factors. Thus,
Plk3 mRNA expression is highest in the G1 phase of the cell
cycle and returns to the basal level in a few hours (17). Despite
the oscillation of the Plk3 mRNA level, its protein level remains
constant throughout the cell cycle. These early observations
demonstrate an apparent disconnection between the mRNA
and protein levels of this protein. The present study confirms
this finding in A549 lung carcinoma cells as we did not detect a
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significant change in the Plk3 protein level after FBS treatment
of serum-starved A549 cells (Fig. 2A). Previous studies showed
that poor correlations between mRNA and protein expression
are common in cellular proteins (37). Plk3 appears to be one of
these proteins. The stable nature of the Plk3 protein appears to
suggest that it may have a very long half-life. However, our
calculated half-life of endogenous Plk3 in A549 cells under normal conditions is about 14 h (Fig. 2G), which is not very long
considering the median half-life of mammalian proteins is 46 h
(38). Ni(II) treatment reduces the half-life of Plk3 to about 8 h
(Fig. 2G). Thus, the apparent stability of the Plk3 protein may be
determined by other mechanisms, e.g. a closely regulated translational process. Further investigation is needed to clarify this.
A previous report showed that ectopically expressed Plk3 is
quickly degraded by UPS in the nucleus (18). Here, we show
that endogenous Plk3 can also be degraded in the cytoplasm via
UPS, particularly in response to Ni(II) or hypoxia. This is an
important observation as most of the Plk3 protein is located in
the cytoplasm (Figs. 2H and 6D).
USP28 is a deubiquitinase that suppresses the stability of
MYC and HIF-1␣ (30, 31, 39). It can be suppressed by Ni(II) via
HIF-, UPS-, and DNA methylation-dependent mechanisms
(32). Because our results show that the HIF pathway is not
directly involved in the suppression of Plk3 by Ni(II) (supplemental Fig. S1), the mechanism underlying the effect of USP28
on Plk3 is likely HIF-independent. Our finding that USP28 prevents the suppression of Plk3 by Ni(II) (Fig. 3, A and D) suggests
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Figure 6. Ni(II) increases both endogenous and ectopically expressed SIAH2. A, HEK293T cells were pretreated with DMSO (vehicle, DM) or 10 M MG132
(MG) for 1 h and then either left untreated (C) or treated with 0.5 mM NiCl2 (Ni) for an additional 6 h. Cells were then harvested for total cellular proteins and
subjected to WB with the indicated antibodies. B, experiment was performed as in A with A549 and HEK293T cells. C, HEK293T cells were transfected with
expression plasmids encoding empty vector (V) or HA-SIAH2-WT (HA-SIAH2). Forty two hours after transfection, cells were either left untreated (C) or treated
with 0.5 mM NiCl2 (Ni) for an additional 6 h. Cells were then harvested and processed as in A. D, A549 cells were either left untreated (C) or treated with 0.5 mM
NiCl2 (Ni) for 12 h. Cell fractionation assay was then performed, and proteins from total lysate (T)/cytosol (C)/nucleus (N) were subjected to WB with the
indicated antibodies. E, A549 cells were treated with normoxia (N) or 1% O2 (H) for 6 h and then processed as in D. F, A549 cells were pretreated with DMSO
(vehicle, DM) or different concentrations of SB203580 (SB) for 2 h and then either left untreated (C) or treated with 0.5 mM NiCl2 (Ni) for an additional 24 h. Cells
were then harvested for WB with the indicated antibodies. Data shown are representatives of three or more independent experiments.
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Figure 7. Proposed model on the mechanism underlying the involvement of Plk3 in HIF signaling and Ni(II) carcinogenesis. Ni(II) suppresses
the cellular level of Plk3 via SIAH2-mediated ubiquitination and proteasome
degradation. Ni(II) may also suppress Plk3 expression by inhibiting its mRNA
expression and by suppressing the USP28-mediated deubiquitination of the
Plk3 protein. Plk3 suppresses the levels of HIF-1␣ and SIAH2 via phosphorylation-dependent mechanisms. Thus, inhibition of Plk3 by Ni(II) elevates the
cellular activities of both the HIF transcription factor and SIAH2 thereby promoting Ni(II)-induced carcinogenesis and tumor progression.

including phosphorylation by protein kinases (e.g. DYRK2,
HIPK2, JNK, and Src) and the deubiquitinase USP13 (23).
These mechanisms are believed to regulate the protein level,
the ligase activity, or the subcellular localization of SIAH2 (23).
Whether these mechanisms also contribute to the regulation of
SIAH2 by Ni(II) remains to be determined. However, it is
known that the PBD of Plk3 binds to phosphorylated protein
motifs and mediates protein-protein interactions via a phosphorylation-dependent manner (40). Because our data show
that Plk3 binds to SIAH2 largely through its PBD, it will be
interesting to learn whether phosphorylation of SIAH2 by
aforementioned kinases triggers its interaction with Plk3
thereby facilitating the mutual regulation of these two proteins.
This newly discovered function of Plk3 is conceivably important for Ni(II) carcinogenesis and tumor progression. Exposure
to Ni(II) elevates the level/activity of SIAH2 thereby suppressing the level of Plk3. This reduces phosphorylation of HIF-1␣
and SIAH2 by Plk3 thereby stabilizing HIF-1␣, promoting the
HIF-dependent hypoxic response, and leading to cell transformation/tumor cell survival. Of note, SIAH2 is considered an
oncogene in multiple tissues, including the lung. It promotes
tumorigenesis through the Ras signaling pathway as well as the
hypoxic response pathway (22, 24). Accordingly, elevated
expression of SIAH2 has been detected in lung cancers (23, 24).
The biological significance of this regulatory network, through
which Plk3 may regulate carcinogenesis, clearly warrants further investigations, particularly in vivo. Fig. 7 outlines the proposed regulatory network involving Plk3 and the potential
mechanism underlying the involvement of Plk3 in Ni(II) carcinogenesis discussed herein.

Experimental procedures
Cell lines and cell culture
BEAS-2B human lung bronchial epithelial cells, A549 human
lung adenocarcinoma cells, and HEK293T cells were obtained
from American Type Culture Collection. Cells were cultured in
J. Biol. Chem. (2017) 292(27) 11431–11444
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that suppression of Plk3 deubiquitination by USP28 in response
to Ni(II) could contribute to the elevated degradation of Plk3 by
UPS. However, the effect of USP28 on Plk3 appears to require
the excessive presence of ubiquitin (Fig. 3, A–F). Moreover, we
were unable to detect a direct interaction between Plk3 and
USP28. These data suggest that USP28 may regulate Plk3 indirectly or that the interaction between the two proteins is weak
and/or transient. Of note, although USP28 has been reported to
mediate HIF-1␣ stability, a direct interaction was also undetectable (39).
The finding that SIAH2 is the E3 ligase for Plk3 is both novel
and significant in our view. This is the first E3 ubiquitin ligase
for Plk3 identified thus far. The fact that SIAH2 is closely associated with the hypoxic response highlights its logical connection to the regulation of HIF signaling by Plk3 (10, 15, 22). This
connection is reinforced by the finding that Plk3, while suppressed by SIAH2, in turn suppresses SIAH2 (Fig. 5). Thus, the
involvement of Plk3 in the cellular hypoxic response appears to
be a lot more complex than previously described (10, 15). Collective evidence supports a new signaling paradigm: under normoxia, Plk3 suppresses the hypoxic response by phosphorylating and destabilizing HIF-1␣ and SIAH2 (10); under hypoxia or
the hypoxia-like condition induced by Ni(II), the level/activity
of SIAH2 increases and the level of USP28 decreases, which
suppress the protein levels of Plk3 and PHDs. Reduced levels
of Plk3 and PHDs in turn help maintain HIF-1␣ and SIAH2
proteins at higher levels. This complex regulatory mechanism potentially puts Plk3 in an important position in a signaling network that functions to fine-tune the cellular
hypoxic response.
It is intriguing that SIAH2 regulates HIF-1 signaling through
both PHDs and Plk3. The reason for cells to have these two
apparently redundant mechanisms may lie in the fact that Plk3
suppresses HIF-1␣ in a pVHL-independent manner, whereas
the inhibition of HIF-1␣ by PHDs requires pVHL (10). The
existence of the SIAH2-Plk3-HIF-1␣ pathway in addition to the
SIAH2-PHD-HIF-1␣ axis would provide an extra layer of safeguard to ensure adequate suppression of the HIF-1 activity
should the pVHL function be compromised. Another important point to consider is that suppression of the Plk3 protein
level by Ni(II) or hypoxia is a relatively slow process that
requires a few hours to occur (Fig. 1, C and D). This feature
suggests that mutual regulation between Plk3 and SIAH2 may
be more functionally relevant to chronic hypoxia or hypoxialike conditions, such as solid tumors or chronic exposure to
Ni(II).
The mechanisms for suppression of the Plk3 level by Ni(II)
and hypoxia are clearly not identical. Other than the finding
that the mechanism for regulation of USP28 by hypoxia and
Ni(II) are not the same (Fig. 3 and supplemental Fig. S1 and
discussion therein), the mechanism underlying the alteration of
SIAH2 by these two conditions may not be identical either.
Previous work showed that hypoxia promotes SIAH2 transcription via an AKT-dependent manner and triggers nuclear
translocation of SIAH2 in a p38-dependent manner (22). Our
data do not seem to support that these mechanisms are responsible for the induction of SIAH2 by Ni(II) (Fig. 6). Hypoxia has
also been shown to regulate SIAH2 via other mechanisms,
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DMEM supplemented with 10% fetal bovine serum (FBS) and
antibiotics (100 units/ml penicillin and 100 g/ml streptomycin sulfate) at 37 °C in a humidified atmosphere containing 5%
CO2. Primary wild-type and PLK3⫺/⫺ MEFs were derived from
embryonic day 14.5 embryos of the respective genotype, produced from the crossing of PLK3⫺/⫺ mice as described previously (15). Primary MEFs were cultured in DMEM supplemented with 15% FBS and antibiotics (as above) under 5% CO2.
Hypoxia was induced by placing cells in a hypoxia/tissue culture chamber (Billups-Rothenberg, Inc.) filled with 1% O2, 5%
CO2, and 94% N2.
Antibodies, reagents, and plasmids

Real-time PCR
Cells were treated and harvested for total RNAs with TRIzol
reagent (Life Technologies, Inc.). Total RNAs were then converted to cDNA using a RT-PCR kit (Clontech) and subjected to
real-time PCR using SYBR Green master mix (Clontech) and a
real-time PCR machine (Stratagene Mx3005P). The primers
used for qPCR are follows: PLK3, 5⬘-TTTTCGCACCACTTTGAGGAC-3⬘/5⬘-GAGGCCAGAAAGGATCTGCC-3⬘; VEGF-A,
5⬘-AGGGCAGAATCATCACGAAGT-3⬘/5⬘-AGGGTCTCGATTGGATGGCA-3⬘; GAPDH (as internal control), 5⬘-ACAACTTTGGTATCGTGGAAGG-3⬘/5⬘-GCCATCACGCCACAGTTTC-3⬘.

Antibodies to P-AKT, P-ERK, P-p38, poly(ADP-ribose) polymerase, HA, and ␣-tubulin were purchased from Cell Signaling Technology. Antibodies to SIAH2, GFP, HA, Fnk, c-Myc,
and GAPDH were purchased from Santa Cruz Biotechnology.
The antibody to HIF-1␣ was purchased from Bethyl Laboratories. The antibody to VEGF-A was purchased from Abcam. The
antibody to M2-FLAG was purchased from Sigma. The Plk3
antibody was obtained from BD Biosciences. MG132 was purchased from Cayman Chemical. Menadione was purchased
from MP Biomedicals. SB203580 was purchased from Abcam.
Scramble control oligonucleotides siRNA (D-001810-0X) and
the siGENOME SMARTpool (M-006561-02) against SIAH2
were purchased from Dharmacon.
pcDNA3-FLAG-HA was a gift from William Sellers (Addgene plasmid 10792). HA-USP28-phCMV2 was a gift from Stephen Elledge (Addgene plasmid 41948). HA-SIAH2-pcDNA3
and HA-SIAH2-RM-pcDNA3 (RING mutant) were kind gifts
from Dr. Ze’ev Ronai at Sanford Burnham Prebys Medical
Research Institute. The plasmid encoding FLAG-tagged ubiquitin has been described previously (41). Plasmids encoding
eGFP-Plk3 full-length (amino acids 1– 646), eGFP-Plk3-KD
(amino acids 1–334), eGFP-Plk3-KDM (KDT219D), and eGFPPlk3-PBD (amino acids 312–646) have been described previously
(15). Constructs of FLAG-Plk3-FL (amino acids 1–646), FLAGPlk3-KD (amino acids 1–334), and FLAG-Plk3-PBD (amino acids
335–646) were generated by inserting appropriate PCR fragments
into the multiple cloning site of p-CMV5-FLAG vector. MISSION
pLKO.1-puro plasmids, non-target shRNA control (SHC016), and
SIAH2-specific (TRCN0000007416) shRNA were purchased from
Sigma. Plasmid transfection was performed using Lipofectamine
reagents from Invitrogen according to the protocol provided by
the manufacturer.

Cells were lysed in the RIPA buffer supplemented with protease and phosphatase inhibitors (50 mM Tris-HCl, pH 7.4, 150
mM NaCl, 2 mM EDTA, 1% Nonidet P-40, 0.1% SDS, 1 mM DTT,
100 mM NaF, 1 mM sodium orthovanadate, 500 M PMSF, 2 M
pepstatin A, 10 M leupeptin). Total cell lysates were then
cleared by centrifugation. One g of antibody and 40 l of protein G-agarose resin (50:50, Thermo Fisher Scientific) were
then added to 1 mg of each cell lysate and incubated at 4 °C for
3 h to overnight followed by extensive washing with the lysis
buffer. Proteins on the resin were then extracted with SDS sample buffer and then subjected to analyses by WB.

Western blotting

Cell fractionation assay

Standard Western blotting procedure was used throughout
the study. SDS-PAGE was carried out using the mini-gel systems from Bio-Rad. Proteins were electrophoretically transferred to PVDF membranes. The membrane was blocked with
TBST containing 5% non-fat dry milk and then incubated overnight with primary antibodies using dilutions suggested by the
manufacturers. After extensive washing with TBST to remove
the primary antibodies, the membrane was then incubated with
secondary antibodies conjugated with HRP for 1 h at room temperature. After extensive washing with TBST, signals on the
membrane were developed using an ECL system (Pierce).

Cell fractionation experiments were carried out on ice or at
4 °C throughout. Cells were washed with ice-cold PBS and collected by centrifugation. Cell pellets were then resuspended
and lysed in Buffer H (10 mM HEPES, pH 7.9, 50 mM NaCl, 0.5 M
sucrose, 0.1 mM EDTA, 0.5% Triton X-100, 1 mM DTT, 100 mM
NaF, 1 mM sodium orthovanadate, and protease inhibitors) as
total cell lysates. After centrifugation for 8 min at 1500 ⫻ g,
supernatants were transferred to fresh tubes and cleared again
by centrifugation for 15 min at 14,000 ⫻ g. The supernatants
after the second centrifugation were kept as cytoplasmic fractions. The pellets after the first centrifugation were washed

For transient RNAi, HEK293T cells were cultured to 30 –50%
confluence and transfected with a scrambled or a SMARTpool
siRNA oligonucleotide targeting SIAH2 using Lipofectamine
2000 reagent according to manufacturer’s provided protocol.
Cells were analyzed 96 h post-transfection. For stable knockdown, non-target control or SIAH2-specific shRNA plasmids
were transfected into HEK293T cells using Lipofectamine reagent followed by selection with 2 g/ml puromycin for 2
weeks.
Protein half-life analysis
Cycloheximide was added to cells at a final concentration of
50 g/ml to block new protein synthesis with or without nickel
treatment. Cells were then harvested at the indicated time
points for WB analysis to detect endogenous Plk3. Signals were
quantified by densitometry and plotted. Half-life from each
group was determined according to the plot.
Immunoprecipitation
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twice with Buffer A (10 mM HEPES, pH 7.9, 10 mM KCl, 0.1 mM
EDTA, 0.1 mM EGTA, 1 mM DTT, and protease inhibitors) and
collected by centrifugation for 10 min at 1500 ⫻ g. The pellets
were then resuspended and lysed in Buffer C (10 mM HEPES,
pH 7.9, 500 mM NaCl, 0.1 mM EDTA, 0.1 mM EGTA, 0.1% Nonidet P-40, 1 mM DTT, and protease inhibitors) followed by
extensive vortexing and centrifugation for 15 min at 14,000 ⫻ g.
The supernatants were transferred to fresh tubes and kept as
nuclear extracts.
Statistical analysis
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